1 Oct 2026, 5:18 pmAGM/EGM
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
AGM PDF
Modern Diagnostic & Research Centre Ltd operates in Healthcare Service Provider within the Healthcare sector.
151 historical price candles were omitted because the exchange source has not been verified.
No red flags triggered.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Standalone figures
| Ratio | Mar 2026 |
|---|---|
| Margins | |
| Gross margin % | 74% |
| EBITDA margin % | 15.2% |
| EBIT margin % | 8.9% |
| PAT margin % | 6.3% |
| Working capital | |
| Receivable days | — |
| Inventory days | 120 |
| Payable days | — |
| NWC days | — |
| Leverage | |
| Current ratio | 1 |
| Debt to EBITDA | — |
| Debt to equity | — |
| Interest coverage | 3.5 |
| Asset turnover | 0.7 |
| Return ratios | |
| Return on assets % | 4.4% |
| Return on capital employed % | 11.2% |
| Return on equity % | — |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
No scheme among the 32 fund houses on record reported a position in Modern Diagnostic & Research Centre Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
Documents link to external sources (exchange filings, company investor pages).
Corporate actions, results dates and filings will appear here once ingested.
| Holder (%) | Dec 2025 | Mar 2026 |
|---|---|---|
| 72.85% | 72.85% | |
| 1.07% | 0.03% | |
| 11.8% | 15.48% | |
| Government | 0% | 0% |
| 14.28% | 11.64% | |
| No. of shareholders | 641 | 282 |
Promoter holding up 0 percentage points since Dec 2025.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB | ₹33,605 Cr | ₹33,605 Cr | ₹2,891 Cr | ₹838 Cr | 28.3% | ₹542 Cr | 18.5% | 28.8% | 21.6% | -79 |
| Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA | ₹14,694 Cr | ₹14,694 Cr | ₹857 Cr | ₹362 Cr | 41.4% | ₹187 Cr | 21.3% | 21.3% | 19.7% | -117 |
| Metropolis Healthcare LimitedMETROPOLISMETROPOLIS | ₹11,151 Cr | ₹11,169 Cr | ₹1,710 Cr | ₹422 Cr | 24.4% | ₹202 Cr | 11.6% | 17.3% | 13.4% | -57 |
| Thyrocare Technologies LimitedTHYROCARETHYROCARE | ₹8,495 Cr | ₹8,495 Cr | ₹876 Cr | ₹282 Cr | 31.6% | ₹176 Cr | 19.6% | 36.5% | 28.8% | 4 |
| Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS | ₹6,509 Cr | ₹6,589 Cr | ₹999 Cr | ₹227 Cr | 22.7% | ₹77 Cr | 7.7% | 17.1% | 9.1% | -61 |
| Suraksha Diagnostic LimitedSURAKSHASURAKSHA | ₹1,824 Cr | ₹1,826 Cr | ₹325 Cr | ₹102 Cr | 30.7% | ₹36 Cr | 10.1% | 16.8% | 14.1% | -101 |
| Krsnaa Diagnostics LimitedKRSNAAKRSNAA | ₹1,798 Cr | ₹2,332 Cr | ₹815 Cr | ₹218 Cr | 27.4% | ₹97 Cr | 13.1% | 13.1% | 10.9% | 65 |
| 3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO | ₹1,416 Cr | ₹1,417 Cr | ₹96 Cr | ₹50 Cr | 52% | ₹163 Cr | 49.4% | 25.3% | 19.4% | 235 |
| One Global Service Provider LtdONEGLOBALONEGLOBAL | ₹1,025 Cr | ₹1,025 Cr | ₹6 Cr | ₹1 Cr | 22.2% | ₹1 Cr | 17.3% | 17.6% | 19.5% | — |
| Health X Platform LimitedHEALTHXHEALTHX | ₹868 Cr | ₹890 Cr | ₹1,468 Cr | ₹-67 Cr | -4% | ₹-20 Cr | -0.1% | — | 0.2% | — |
| Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF | ₹797 Cr | ₹820 Cr | ₹104 Cr | ₹38 Cr | 36.1% | ₹24 Cr | 23.4% | 23.1% | 16.1% | 92 |
| Aspira Pathlab & Diagnostics LtdASPIRAASPIRA | ₹135 Cr | ₹136 Cr | ₹22 Cr | ₹4 Cr | 16% | ₹2 Cr | 9.2% | 17.5% | 18.1% | 16 |
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Shareholder Meeting / Postal Ballot-Outcome of AGM
Closure of Trading Window
Clarification On Significant Movement In The Price Of The Securities Of The Company
Clarification sought from Modern Diagnostic & Research Centre Ltd
Announcement under Regulation 30 (LODR)-Newspaper Publication
Reg. 34 (1) Annual Report.
Revised Letter Attached In The Intimation For 14Th AGM Of The Company
| Date | Category | Subject | Filing |
|---|---|---|---|
| 1 Oct 2026, 5:18 pm | AGM/EGM AGM | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | |
| 30 Sept 2026, 5:42 pm | AGM/EGM AGM | Shareholder Meeting / Postal Ballot-Outcome of AGM |
| 28 Sept 2026, 8:57 pm | Insider Trading / SAST Closure of Trading Window | Closure of Trading Window |
| 15 Sept 2026, 2:35 pm | Company Update General | Clarification On Significant Movement In The Price Of The Securities Of The Company |
| 15 Sept 2026, 12:40 pm | Company Update Clarification | Clarification sought from Modern Diagnostic & Research Centre Ltd | — |
| 6 Sept 2026, 12:29 pm | Company Update Newspaper Publication | Announcement under Regulation 30 (LODR)-Newspaper Publication |
| 5 Sept 2026, 4:17 pm | Others Reg. 34 (1) Annual Report | Reg. 34 (1) Annual Report. |
| 5 Sept 2026, 3:33 pm | AGM/EGM AGM | Revised Letter Attached In The Intimation For 14Th AGM Of The Company |
| ₹ Cr | Mar 2026 |
|---|---|
| Revenue | 83 |
| COGS | 22 |
| Gross profit | 62 |
| 49 | |
| Operating profit (EBITDA) | 13 |
| OPM % | 15.2% |
| Depreciation | 5 |
| Interest | 2 |
| 1 | |
| Profit before tax | 6 |
| Tax | 1 |
| Tax % | 12.4% |
| PAT | 5 |
| PAT margin % | 6.3% |
| EPS (₹) | 3.5 |
| ₹ Cr | Mar 2026 |
|---|---|
| Equity capital | — |
| Reserves | — |
| Borrowings | — |
| 119 | |
| Total equity & liabilities | 119 |
| Fixed assets | 47 |
| CWIP | — |
| Investments | 17 |
| 55 | |
| Total assets | 119 |
| ₹ Cr | Mar 2026 |
|---|---|
| 4 | |
| -40 | |
| 45 | |
| Net cash flow | 9 |
| Free cash flow | -19 |
| CFO / Operating profit % | 30.3% |